The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression
Journal of Endocrinological Investigation · 30.09.2024 · 48 (2) · 283-294
DOI: 10.1007/s40618-024-02459-3 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 30.09.2024. Verfasst von Moein Ala und 1 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Medicine Research Center, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran. moinala75@yahoo.com. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Blood Pressure, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Medicine Research Center, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran. moinala75@yahoo.com.
- Experimental Medicine Research Center, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Zitieren
APA
Ala, M., & Moheb Aleaba, M. (2024). The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. Journal of Endocrinological Investigation, 48(2), 283-294. https://doi.org/10.1007/s40618-024-02459-3
Vancouver
Ala M, Moheb Aleaba M. The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. Journal of Endocrinological Investigation. 2024;48(2):283-294. doi:10.1007/s40618-024-02459-3
BibTeX
@article{Ala2024,
author = {Ala, Moein and Moheb Aleaba, Mohammadreza},
title = {The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression},
journal = {Journal of Endocrinological Investigation},
year = {2024},
volume = {48},
number = {2},
pages = {283--294},
doi = {10.1007/s40618-024-02459-3}
}
EUVIMED